BoonHuey Ee – General Manager, Merck Biopharma Taiwan
BoonHuey Ee, general manager of Merck Biopharma Taiwan, shares her story of joining the affiliate at the beginning of last year and goes on to offer insights on the strengths…
In order to obtain genetic information for analysis and their applications for developing new drugs, precise and qualitative nucleic acid extraction steps are essential. This is Viogene’s primary focus. Viogene provides innovative and cutting-edge nucleic acids extraction technologies and products to allow scientists achieve their goals. Viogene currently has more than 40 nucleic acids extraction products for extracting nucleic acids from various biological sources such as animals, plants, microorganisms. Viogene sells its products in more than 30 countries worldwide.
Another part of Viogene’s research and development program is a platform of G protein coupled receptors (GPCRs) related drugs screening from traditional Chinese medicines (TCMs), GPCRs have proved to be very successful drug targets for more than 30% of marketed drugs which target directly or indirectly on GPCRs, which including the top 100 brand name prescription drugs, however mitigating side effects and increasing potency of GPCRs related drugs are marketed needed, Viogene’s GPCRs new drug screening and discovering programs from TCMs offer new solutions and opportunities for achieving the goals.
No.276, Ta-Tung Rd., Sec.1, Shijr,
New Taipei City, Taiwan
PHONE: 886 2 26472259
FAX: 886 2 26475094
Website: www.viogene.com
BoonHuey Ee, general manager of Merck Biopharma Taiwan, shares her story of joining the affiliate at the beginning of last year and goes on to offer insights on the strengths…
Taiwan’s biotech sector is growing rapidly and increasingly embracing advanced fields such as precision medicine and AI. However, Johnsee Lee, chairman of the Taiwan Bio Industry Organization warns that the island’s…
Rita Huang, dean of the Office of Research and Development and the director of the TMU Research Center for Cell Therapy and Regeneration Medicine highlights the center’s unique capabilities and…
NYMU President Dr Steve Kuo describes the history of the university and transformative period it is currently undergoing. Dr Kuo shares the university’s key strengths and unique strategy to merge…
Dr Michael Chang, founder and chairman of OBI Pharma, shares the history of his company’s beginnings and highlights the current progress of its innovative immune-oncology pipeline. Dr Chang goes on…
Shih-Chung Chen, Minister of Health and Welfare of the Republic of China (Taiwan), gives an update on the Ministry’s current directives under the Biomedical Industry Innovation Program to bolster Taiwan’s…
Dr Hung-Kai Kevin Chen, co-founder and CEO of Elixiron Immunotherapeutics, an innovative rising biotech focused on immunotherapeutic solutions, describes the company’s unique approach to developing new treatment methods for two…
Johnsee Lee, chairman of Taiwan Bio Industry Organization, gives an update on the major developments of the country’s biotech environment over recent years, speaking about its new areas of focus,…
Professor Chi-Hung Lin of NCTU discusses the opportunities and hurdles for unveiling smart healthcare in Taiwan. He also assesses Taiwan’s position in the global race for smart healthcare, and how…
Dar-Bin Shieh, deputy minister of science and technology of the Republic of China (Taiwan), gives an overview of Biomedical Industry Innovation Program, enacted to bolster Taiwan’s biomedical and biotechnology sectors…
Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health…
Taiwan’s Minister of Economic Affairs, Jong-Chin Shen, outlines the initiatives implemented by the Ministry to help Taiwan’s industries reinforce their competitive advantage. Minister Shen also goes on to explain the…
See our Cookie Privacy Policy Here
